Evlabio
Biologics & Biosimilars
Overview
Creating innovative therapies for chronic kidney disease patients. Addressing left ventricular hypertrophy with monoclonal antibody treatments.
Funding and backers
Team
11-50
employees, estimated range
Backers
3
High-Tech Gründerfonds, AdBio
Momentum
0/100
no fresh signals
Backed byfrom the funds' portfolios and accelerator catalogs
High-Tech Gründerfonds 
AdBio 
Kurma Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
Caedo Oncology AS develops new strategies for monoclonal anti-body based therapy. Learn more about our research and how we work.
AI-Powered Support for Chronic Kidney Disease Care.
Extended-release RNA medicines that turn transient treatments into durable therapies for chronic disease. ScionxBio uses synthetic…
Antiverse combines generative AI and advanced antibody discovery to design functional, developable biologics for challenging drug targets.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely